JP2018126316A - Anticancer agent-containing urine adsorption sheet body - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an anticancer agent-containing urine adsorption sheet body that is effective as a secondary exposure measurement in a hospital for patients, medical workers, persons concerned in the hospital, or the like, by absorbing urine containing an agent having high toxicity such as an anticancer agent and adsorbing the agent in the urine.SOLUTION: A urine absorption sheet body 1S comprises a laminate of: an agent-containing urine absorption layer part 10a for absorbing agent-containing urine containing agent molecules of an anticancer agent; an agent-containing urine transmission part 20 for transmitting agent-containing urine, the agent-containing urine transmission part being arranged on a side of a first face 18 of the agent-containing urine absorption layer part; and a transmission prevention part 30 for preventing leakage of agent-containing urine, the transmission prevention part being arranged on a side of a second face 19 of the agent-containing urine absorption layer part. The urine absorption sheet body is to be arranged around a bedpan. The agent-containing urine absorption layer part comprises: an active carbon-containing sheet-like member 11 containing adsorbed active carbon; and a fibrous urine-absorbing sheet member 12. The adsorbed active carbon has a physical property having the average pore diameter of 1.7 to 5nm. The agent-containing urine transmission part is a cloth-like member of resin fiber. The transmission prevention part is a resin sheet member.SELECTED DRAWING: Figure 1

Description

  The present invention relates to an anticancer agent-containing urine adsorbent sheet, and more particularly to an anticancer agent-containing urine adsorbent sheet that adsorbs an anticancer agent contained in urine scattered around the toilet.

  An anticancer agent is a preparation that suppresses the growth of cancer cells and ultimately suppresses or kills the growth. Its mechanism of action is to penetrate into the target cancer cell and inhibit DNA replication and synthesis of the cell, inhibition of microtubule formation (inhibition of cell division), inhibition of intracellular metabolism or control of nutrient supply blood flow, etc. cause. Therefore, anticancer agents act on cancerous cells to cause cell death such as apoptosis, but are highly toxic to normal cells. For this reason, handling of anticancer drugs requires caution.

  Currently, in order to cope with various types of cancer, many chemotherapy using anticancer drugs are taken in. In anticancer drug treatment, the individual dose of an anticancer drug is determined by a doctor and dispensed into an infusion container (infusion bag) or the like by a pharmacist based on the prescription. Looking at the work of preparing this anticancer drug in more detail, the anticancer drug splashes and aerosols scattered from injection needles, chemical bottles, infusion solutions, etc., adhere to the skin of pharmacists, etc. There is primary exposure to inhalation. In addition, there is secondary exposure that adheres to the skin of a pharmacist or the like through a drug bag, a bottle, or the like that is in contact with the splashed anticancer drug droplets. In particular, the preparation of an anticancer agent is performed by a specialized pharmacist. Therefore, the danger of occupational anticancer drug exposure of medical workers such as pharmacists and nurses has been pointed out. In particular, there have been reports of miscarriages, leukemias, bladder cancer, etc. of medical workers themselves due to long-term work engagement. Therefore, it is very important for healthcare professionals to take measures against exposure to anticancer drugs.

  In the current preparation of anticancer agents, waterproof apron, double gloves and activated carbon mask are worn. Anticancer drug preparation work is performed in an environment that reduces the scattering of drugs such as biological safety cabinets and closed-type preparation devices that do not allow aerosols generated during preparation to flow out. However, in reality, environmental pollution is not completely prevented. The anticancer agent preparation work is disclosed, for example, by the invention of a training kit, and training is performed using the training kit (see Patent Document 1). In this case, the liquid absorbing sheet is laid on the work table of the safety cabinet.

  Usually, the anticancer agent splashes scattered during the preparation of the anticancer agent are adsorbed on a work sheet placed in the work environment, and it is considered that secondary diffusion in the work environment is suppressed. However, even in the current guidelines, the work sheet is only specified as “the front surface is a water-absorbing material and the back surface is a drug-impermeable material”. In other words, the current working sheet is not a sheet developed exclusively for the preparation of anticancer agents. Therefore, the liquid-absorbing sheet used is actually a substitute for a pulp-made sheet for the purpose of absorbing surgical-related sterilized drapes, blood, bodily fluids, or excreta. Therefore, adsorption of anticancer agents is not always sufficient in existing work sheets.

  Moreover, the following structure is known as the technique of the existing liquid absorption sheet. For example, it is a laminated sheet in which paper is pasted on both surfaces of a highly water-absorbing material, and a nonwoven fabric is further pasted on the paper (see Patent Document 2). Or it is the laminated sheet which the activated carbon containing sheet | seat was provided and laminated | stacked between the two pulp sheets (refer patent document 3). In the case of an existing liquid absorbent sheet, improvement in water absorption (liquid absorption) performance is mainly regarded as improvement in the liquid absorption amount. However, when anticancer drug preparation work is kept in mind, a higher performance is required such that a solution containing a drug such as an anticancer drug is properly permeated, adsorbed, and finally retained. The Therefore, it is self-evident that the existing liquid absorbent sheet still does not have a sufficient level of performance in pursuit of safety.

  In parallel with the aforementioned problem of exposure to drugs during preparation of anticancer drugs, exposure due to anticancer drug components contained in the urine of patients undergoing anticancer drug treatment is also regarded as a problem. Of the anticancer drugs taken into the patient's body by infusion, oral administration, etc., excess drug molecules of the anticancer drug are mixed in urine and excreted outside the body. That is, an anticancer agent is contained in the patient's urine, and the excreted urine causes secondary diffusion.

  Specifically, since the urine excreted toward the toilet bowl collides with the toilet surface and scatters around the toilet bowl, the area around the urinal (mainly a male urinal) is remarkable. Then, other patients, medical workers, etc. have many opportunities to come into contact with urine containing an anticancer agent. In addition, a person who cleans the toilet bowl and its surroundings constantly comes into contact with the urine containing the anticancer drug through the cleaning work. Therefore, a cleaning worker in a chemotherapy ward must wear gloves, a mask, protective glasses, and an apron when cleaning the toilet bowl and its surroundings. However, suppression of secondary diffusion of the anticancer agent contained in urine scattered around the toilet is not sufficient.

  From a series of circumstances, in addition to taking measures against exposure of anti-cancer drugs by medical staff in the safety cabinet, it is possible to absorb drugs through absorption of urine containing highly toxic drugs such as anti-cancer drugs in hospitals or ward environments. There is a need for more specialized and higher performance urine adsorbent sheet bodies.

Japanese Patent No. 5062685 Japanese Patent No. 2862274 Japanese Patent No. 4301633

  Thereafter, the inventors have continued to intensively study materials used in the liquid absorbent sheet in order to improve the adsorption performance and retention performance of highly toxic drugs such as anticancer agents in the liquid absorbent sheet. As a result, the urine permeation performance of scattered urine is improved, the drug component contained in the urine is selectively adsorbed inside, and an anticancer agent-containing urine adsorbent sheet body effective for measures against external diffusion of the drug component is obtained. It came to develop.

  The present invention has been made in view of the above points, and absorbs urine containing a highly toxic drug such as an anticancer drug, and adsorbs the drug contained in the urine to engage a patient and a medical professional. Provide an anticancer agent-containing urine adsorbent sheet body that is effective for measures against secondary exposure in hospitals, which has improved safety for persons involved in hospitals and hospitals.

  That is, the first invention includes a drug-containing urine absorption layer part that absorbs drug-containing urine containing drug molecules of an anticancer drug, and a drug-containing urine disposed on the first surface side of the drug-containing urine absorption layer part. A drug-containing urine permeation part that permeates the drug-containing urine absorption layer part side, and a leakage of the drug-containing urine from the drug-containing urine absorption layer part side disposed on the second surface side of the drug-containing urine absorption layer part A urine absorbing sheet body provided with a permeation preventing part to be laminated, wherein the urine absorbing sheet body is disposed around a toilet, and the drug-containing urine absorbing layer part includes an activated carbon-containing sheet-like member containing adsorbed activated carbon And a fibrous urine absorbing sheet member, the adsorbed activated carbon has a physical property of an average pore diameter of 1.7 to 5 nm, and the drug-containing urine permeable portion is a resin fiber cloth-like member And the permeation preventing portion is a resin sheet member. According to Cancer-containing urine suction sheet body.

  In the second aspect of the invention, the activated carbon-containing sheet-like member is disposed on the first surface side of the drug-containing urine absorption layer portion, and the fibrous urine absorption sheet member is on the second surface side of the drug-containing urine absorption layer portion. The anti-cancer agent-containing urine adsorbing sheet body according to the first invention is provided.

  According to a third aspect of the present invention, there is provided a drug-containing urine absorption layer part that absorbs drug-containing urine containing drug molecules of an anticancer drug, and the drug-containing urine disposed on the first surface side of the drug-containing urine absorption layer part. A drug-containing urine permeation part that permeates to the drug-containing urine absorption layer part side, and a permeation that is arranged on the second surface side of the drug-containing urine absorption layer part and prevents leakage of the drug-containing urine from the drug-containing urine absorption layer part side A urine absorption sheet body provided with a stack of prevention parts, the urine absorption sheet body is disposed around a toilet, and the drug-containing urine absorption layer part includes an activated carbon-containing sheet-like member containing adsorbed activated carbon; A water-swellable resin member and a fibrous urine absorbing sheet member are provided, and the adsorbed activated carbon has physical properties such that an average pore diameter is 1.7 to 5 nm. The permeation preventive part is a resin sheet member. According to an anticancer agent containing the urine suction sheet body to symptoms.

  According to a fourth aspect of the present invention, the activated carbon-containing sheet-shaped member is disposed on the first surface side of the drug-containing urine absorbing layer portion, and the fibrous urine absorbing sheet member is disposed on the second surface side of the drug-containing urine absorbing layer portion. The anti-cancer agent-containing urine adsorbing sheet body according to the third aspect, wherein the water-swellable resin member is provided between the activated carbon-containing sheet-like member and the fibrous urine absorbing sheet member Concerning.

  A fifth invention relates to the anticancer agent-containing urine adsorbent sheet according to any one of the first to fourth inventions, wherein the drug molecule is a non-volatile molecule.

  A sixth invention relates to the anticancer agent-containing urine adsorbent sheet according to any one of the first to fifth inventions, wherein the drug molecule has a molecular weight of 100 to 1,000.

In a seventh aspect of the present invention, the adsorbed activated carbon further has a pore volume of pores having a pore diameter of 1 to 100 nm per unit weight of the adsorbed activated carbon of 0.08 cm ³ / g or more in the measurement by the DH plot method. The anti-cancer agent-containing urine adsorbing sheet according to any one of the first to sixth inventions having physical properties.

  The eighth invention is the invention according to any one of the first to seventh inventions, wherein the drug-containing urine permeation part has a water retention rate of 500% or less in a water retention test in accordance with JIS L 1913 (2010). The present invention relates to an anticancer agent-containing urine adsorption sheet body.

  A ninth invention relates to the anticancer agent-containing urine adsorbent sheet according to any one of the first to eighth inventions, wherein the drug-containing urine permeation part is a nonwoven fabric of synthetic resin fibers.

A tenth aspect of the present invention relates to the anticancer agent-containing urine adsorbing sheet according to any one of the first to ninth aspects, wherein the basis weight of the fibrous urine absorbing sheet member is 10 g / m ² or more.

  An eleventh aspect of the invention relates to the anticancer agent-containing urine adsorbing sheet according to any one of the first to tenth aspects, wherein a non-slip portion is provided on the back surface of the permeation prevention portion.

  In a twelfth aspect of the urine absorption sheet body, the thickness when the drug-containing urine permeation part, the drug-containing urine absorption layer part, and the permeation prevention part are laminated is 0.3 to 5 mm. The anticancer agent-containing urine adsorbing sheet according to any one of the first to eleventh inventions.

  A thirteenth invention relates to the anticancer agent-containing urine adsorbing sheet body according to any one of the first to twelfth inventions, wherein the fibrous urine absorbing sheet member is formed of a cellulose component.

  According to the anticancer agent-containing urine adsorbing sheet body according to the first invention, a drug-containing urine absorption layer part that absorbs drug-containing urine containing drug molecules of the anticancer drug, and the drug-containing urine absorption layer part A drug-containing urine permeation part that is disposed on the first surface side and permeates the drug-containing urine to the drug-containing urine absorption layer side; and a drug-containing urine absorption layer that is disposed on the second surface side of the drug-containing urine absorption layer part It is a urine absorption sheet body provided with a permeation prevention unit that prevents leakage of drug-containing urine from the part side, the urine absorption sheet body is disposed around a toilet, and the drug-containing urine absorption layer part is While having an activated carbon-containing sheet-like member containing adsorbed activated carbon and a fibrous urine-absorbing sheet member, the adsorbed activated carbon has physical properties with an average pore diameter of 1.7 to 5 nm, and the drug-containing urine The transmission part is a cloth-like member of resin fiber, and the transmission prevention part is a resin sheet. Because it is a component, it absorbs urine containing a highly toxic drug such as an anticancer drug with its ability to absorb liquids, and adsorbs the drug contained in the urine to help patients, healthcare professionals, and hospitals It is effective for measures against secondary exposure in hospitals that improve the safety of the elderly.

  According to the anticancer agent-containing urine adsorbing sheet body according to the second invention, in the first invention, the activated carbon-containing sheet-like member is disposed on the first surface side of the drug-containing urine absorption layer portion, and the fibrous Since the urine-absorbing sheet member is arranged on the second surface side of the drug-containing urine absorption layer part, the moisture or the like of the drug-containing urine that could not be absorbed by the drug-containing urine absorption layer part is directly below the fibrous liquid absorption sheet It can be absorbed by the member.

  According to the anticancer agent-containing urine adsorbing sheet body according to the third invention, the drug-containing urine absorption layer portion that absorbs the drug-containing urine containing the drug molecule of the anticancer agent, and the drug-containing urine absorption layer portion A drug-containing urine permeation part that is disposed on the first surface side and permeates the drug-containing urine to the drug-containing urine absorption layer side; and a drug-containing urine absorption layer that is disposed on the second surface side of the drug-containing urine absorption layer part It is a urine absorption sheet body provided with a permeation prevention unit that prevents leakage of drug-containing urine from the part side, the urine absorption sheet body is disposed around a toilet, and the drug-containing urine absorption layer part is While having an activated carbon-containing sheet-like member containing adsorbed activated carbon, a water-swellable resin member, and a fibrous urine absorbing sheet member, the adsorbed activated carbon has a physical property with an average pore diameter of 1.7 to 5 nm. The drug-containing urine permeable part is a cloth-like member of resin fiber, Since the prevention part is a resin sheet member, it absorbs urine containing a highly toxic drug such as an anticancer drug with a higher liquid absorption capacity and adsorbs the drug contained in the urine to the patient It is effective for measures against secondary exposure in hospitals that improve the safety of medical workers, hospital staff, etc.

  According to the anticancer agent-containing urine adsorbing sheet body according to the fourth invention, in the third invention, the activated carbon-containing sheet-like member is disposed on the first surface side of the drug-containing urine absorption layer portion, and the fibrous A urine-absorbing sheet member is disposed on the second surface side of the drug-containing urine absorbing layer portion, and the water-swellable resin member is provided between the activated carbon-containing sheet-like member and the fibrous urine-absorbing sheet member. Therefore, the water or the like of the drug-containing urine that cannot be absorbed by the drug-containing urine absorption layer can be absorbed by the water-swellable resin member and the fibrous liquid-absorbing sheet member directly below.

  According to the anticancer agent-containing urine adsorbent sheet according to the fifth invention, in any one of the first to fourth inventions, since the drug molecule is a non-volatile molecule, the risk of percutaneous absorption is reduced. Is done.

  According to the anticancer agent-containing urine adsorbing sheet according to the sixth invention, in any one of the first to fifth inventions, the molecular weight of the drug molecule is 100 to 1000. The drug molecules of the drug are almost covered.

According to the anticancer agent-containing urine adsorbent sheet according to the seventh invention, in any one of the first to sixth inventions, the adsorbed activated carbon is further per unit weight of the adsorbed activated carbon in the measurement by the DH plot method. Therefore, drug molecules having a wide range of molecular weight can be adsorbed since the pore volume of the pores having a pore diameter of 1 to 100 nm is 0.08 cm ³ / g or more.

  According to the anticancer agent-containing urine adsorbent sheet according to the eighth invention, in any one of the first to seventh inventions, the drug-containing urine permeable portion has a water retention rate in accordance with JIS L 1913 (2010). In the test, since the water retention rate is 500% or less, the drug-containing urine permeates and is absorbed by the drug-containing urine absorption layer, and the drug molecules are adsorbed. And the exposure of the drug molecule | numerator in the surface part of a chemical | medical agent containing urine permeation | transmission part is suppressed as much as possible, and the safety | security of a chemical | medical agent containing urine liquid absorption sheet body increases by the effect | action of containment.

  According to the anticancer agent-containing urine adsorbent sheet according to the ninth invention, in any one of the first to eighth inventions, the drug-containing urine permeable portion is a nonwoven fabric of synthetic resin fibers, It is suppressed.

According to the anticancer agent-containing urine adsorbing sheet body of the tenth invention, in the first to ninth inventions, the basis weight of the fibrous urine absorbing sheet member is 10 g / m ² or more, The amount of drug-containing urine absorbed by the drug-containing urine absorption layer generally increases due to the water retention effect of the fibrous urine absorbing sheet member.

  According to the anticancer agent-containing urine adsorbing sheet according to the eleventh invention, in any one of the first to tenth inventions, the back surface of the permeation preventive portion is provided with a non-slip portion. Misalignment is suppressed.

  According to the anticancer agent-containing urine adsorbing sheet body of the twelfth invention, in any one of the first to eleventh inventions, the drug-containing urine permeation portion and the drug-containing urine absorption in the urine absorption sheet body Since the thickness when the layer portion and the permeation preventive portion are laminated is 0.3 to 5 mm, the level difference is reduced, and the patient's falls can be reduced.

  According to the anticancer agent-containing urine adsorbing sheet according to the thirteenth invention, in any one of the first to twelfth inventions, the fibrous urine absorbing sheet member is formed of a cellulose component. The hydrophilicity of is utilized for liquid absorption.

It is sectional drawing of the anticancer agent containing urine adsorption sheet body of 1st Embodiment of this invention. It is sectional drawing of the anticancer agent containing urine adsorption sheet body of 2nd Embodiment of this invention. It is the whole photograph of the produced anticancer agent adsorption sheet body. It is a photograph at the time of use of an anticancer agent containing urine adsorption sheet body.

  The anti-cancer agent-containing urine adsorbent sheet of the present invention absorbs urine excreted from a chemotherapy patient to whom an anti-cancer agent or the like has been administered, whereby drug molecules of the anti-cancer agent contained in the urine Is a urine absorbing sheet body that selectively adsorbs and suppresses secondary diffusion of anticancer agents around the toilet. Specifically, the urine excreted toward the toilet (urinal, mainly male urinal) collides with the toilet and then splashes to the surroundings and adheres to the wall or floor around the toilet. Therefore, when the urine absorbing sheet body is previously arranged around the toilet bowl, the scattered urine is absorbed, and the drug molecules of the anticancer drug contained in the urine are held in the urine absorbing sheet body. Diffusion is suppressed. The anticancer agent-containing urine adsorption sheet body of the present invention is a urine absorption sheet body for such use (see the photograph in FIG. 4). Hereinafter, the structure and characteristics of the anticancer agent-containing urine adsorbing sheet body of the embodiment will be described in order with respect to the urine absorbing sheet body, using cross-sectional views.

  As described in the background art, the preparation of an anticancer agent is generally performed in a safety cabinet. Since the inside of the cabinet has a negative pressure, the volatile components diffused inside are sucked into the cabinet. However, when the drug molecule is non-volatile, there is an increased risk of penetrating into the body through the hands and arms of the medical staff from the site where the scattered droplets are attached. In addition, during dispensing, anticancer drug droplets scattered inside the safety cabinet may adhere to drug bags, bottles, other equipment, etc. brought into the safety cabinet. Certainly, anticancer drug molecules may diffuse outside the safety cabinet through their attachment. However, preparation of anticancer drugs in the safety cabinet is performed by a medical staff such as an experienced pharmacist, and therefore it is easy to thoroughly manage drug diffusion.

  On the other hand, in the case of a toilet in a chemical treatment ward for anticancer drug treatment, the patient himself and other patients who are taking medication use it or a cleaning worker or the like cleans it. In this way, a large number of unspecified persons, particularly those who are vulnerable to drug diffusion, are often used. For this reason, suppression of secondary diffusion of drug molecules of anticancer drugs and exposure measures are significant. If anticancer drug molecules are non-volatile molecules at room temperature in the urine excreted from patients undergoing treatment with anticancer drugs, they adhere to the walls, floors, etc. The risk of percutaneous absorption from is further increased. Therefore, when an anticancer agent-containing urine adsorbing sheet (urine absorbing sheet) is placed on the wall, floor, etc. around the toilet bowl, the drug-containing urine containing nonvolatile drug molecules is absorbed into the sheet, The risk of skin absorption is reduced.

  The anti-cancer agent-containing urine adsorbent sheet body mainly absorbs drug-containing urine containing drug molecules having a molecular weight of 100 to 1,000. The drug molecule in the molecular weight range has a molecular weight corresponding to the current mainstream anticancer agent. Moreover, it is a drug-containing urine containing non-volatile drug molecules. Unlike ammonia (molecular weight: 17.03) in urine and the like, drug molecules in the molecular weight range are considered to hardly volatilize at room temperature.

  Here, typical anticancer agents and their molecules are paclitaxel (molecular weight: 853.91), cyclophosphamide (molecular weight: 279.10), irinotecan (molecular weight: 677.18), 5-fluorouracil (molecular weight). : 130.08), adriamycin (molecular weight: 579.98), methotrexate (molecular weight: 454.44), dacarbazine (molecular weight: 182.18), cytarabine (molecular weight: 243.22), vincristine (molecular weight: 923.04) , Gemcitabine (molecular weight: 299.66), mitoxantrone (molecular weight: 517.40), mitomycin (molecular weight: 334.33), epirubicin (molecular weight: 543.52), etoposide (molecular weight: 588.56), cisplatin ( Molecular weight: 300.05), carboplatin (molecular weight: 37) .25) are listed as such.

  Taking into account the molecular weight range of the listed drug molecules, it converges in the range of approximately 100 to 1000. In other words, drug molecules of currently prescribed anticancer drugs are almost covered. Therefore, when molecular adsorption in the molecular weight range of 100 to 1000 is realized, the risk of secondary diffusion through urine containing an anticancer agent is greatly reduced.

[First Embodiment]
A sectional view (schematic diagram) of FIG. 1 shows an anticancer agent-containing urine adsorbing sheet body 1A of the first embodiment. The anticancer agent-containing urine adsorption sheet body 1A is provided with a drug-containing urine absorption layer portion 10a at the center thereof. The drug-containing urine permeation part 20 is disposed and provided on the first surface side (the upper side in the drawing) of the drug-containing urine absorption layer part 10a. At the same time, the permeation preventing unit 30 is disposed and provided on the second surface side (lower side in the drawing) of the drug-containing urine absorption layer unit 10a. Therefore, the urine absorption sheet body 1S which is the main body portion of the anticancer agent-containing urine adsorption sheet body 1A includes three layers of the drug-containing urine permeation part 20, the drug-containing urine absorption layer part 10a, and the permeation prevention part 30. It is formed as a laminated structure. In the figure, reference numeral 50 denotes an anti-slip portion.

<Drug-containing urine absorption layer>
The role of the drug-containing urine absorbing layer 10a is to absorb urine scattered during excretion and to adsorb drug molecules of the anticancer drug contained in the urine to prevent leakage outside the sheet body. That is. Therefore, the drug-containing urine absorption layer portion 10a includes an activated carbon-containing sheet-like member 11 and a fibrous urine-absorbing sheet member 12.

  Adsorbed activated carbon is used for the adsorption of drug molecules in the drug-containing urine absorption layer 10a. Furthermore, in order to cope with absorption in the state of drug-containing urine, a material having excellent liquid absorbency is also required. In addition, since it is disposable (one-use), it needs to be finished at a low cost. Taking this into consideration, the drug-containing urine absorption layer portion 10a is provided with an activated carbon-containing sheet-like member containing adsorbed activated carbon.

  Adsorbed activated carbon has physical properties with an average pore diameter of 1.7 to 5 nm as described in the following examples in consideration of the adsorption of drug molecules having a molecular weight in the range of 100 to 1000 (see the medicinal ingredients of the above-mentioned anticancer agents). Is selected from activated carbons exhibiting In the case of activated carbon having an average pore diameter of less than 1.7 nm, the average pore diameter is small and unsuitable for the adsorption of drug molecules. In the case of activated carbon having an average pore diameter of more than 5 nm, it is considered that the average pore diameter is too large, and the drug molecules that have entered the pores are insufficiently collected (fixed) and desorbed.

In addition to the physical properties of the average pore diameter, the physical properties of the pore volume are further added to the adsorbed activated carbon. In this case, in the analysis of the pore distribution of the adsorbed activated carbon by the DH plot method (Dollimore-Heal method, DH method), the pore volume of the pore having a pore diameter of 1 to 100 nm per unit weight of the adsorbed activated carbon is 0.08 cm. ^The physical property is ³ / g or more. In general, the DH plot method can relatively easily grasp distribution analysis of mesopores having a diameter of 1 nm to 100 nm. Therefore, the DH plot method is advantageously used for analyzing pores having a distribution including the diameter range.

Although the upper limit of the pore volume per unit weight of the adsorbed activated carbon varies depending on the type of activated carbon used, the activation method, and the like, it is considered to be approximately 2 cm ³ / g from the tendency of Examples described later. When the pore volume is less than 0.08 cm ³ / g, since the amount of pores in the activated carbon is small, the ability to adsorb drug molecules decreases. In particular, considering the shape of the anticancer agent-containing urine adsorbing sheet, a large amount of activated carbon cannot be filled. Under such constraints, a wide range of molecular weight drug molecules must be adsorbed efficiently. Therefore, the index of the DH plot method is significant in the sense that the pore volume per unit weight of the adsorbed activated carbon can be evaluated.

  The raw materials of the adsorbed activated carbon are coconut shell, large saw powder (Ogako), waste material, waste bamboo, coal, petroleum pitch, phenol resin, and the like. After these raw materials are carbonized, activation treatment such as steam activation, zinc chloride activation, phosphoric acid activation, sulfuric acid activation, air activation, carbon dioxide activation, etc. is applied. As a result, pores develop in the activated carbon.

  As described in detail above, adsorbed activated carbon has physical properties of pores corresponding to the molecular weight of drug molecules such as currently mainstream anticancer agents. Therefore, the anticancer agent-containing urine adsorbent sheet body is effective in efficiently adsorbing drug molecules and maintaining the state. However, when holding the adsorbed activated carbon, the activated carbon alone cannot absorb and hold the moisture of the drug-containing urine well. Therefore, the adsorbed activated carbon is in the form of an activated carbon-containing sheet-like member 11.

  The activated carbon-containing sheet member 11 is a sheet in which, for example, a fibrous material and adsorbed activated carbon are mixed. The fibrous material is selected from fiber materials such as cotton, hemp and rayon in addition to paper and pulp having relatively high water absorption. The combination of these fibrous materials and adsorbed activated carbon is appropriate. For example, the adsorbed activated carbon is sandwiched between thin layers such as paper and cloth (woven fabric, non-woven fabric). Alternatively, paper, fibers, etc. are made into a slurry, and the adsorbed activated carbon is dispersed therein, and then finished into a sheet according to the paper making procedure. It is formed by a method similar to so-called papermaking. In this way, the drug-containing urine absorption layer portion 10 is formed.

  Further, the drug-containing urine absorbing layer portion 10a is provided with a fibrous urine absorbing sheet member 12 in addition to the activated carbon-containing sheet member 11 described above. The fibrous urine absorbing sheet member 12 is formed from a known fibrous material rich in water absorption. Specifically, it is a sheet member such as a woven fabric, a non-woven fabric, or a pulp raw material paper formed from cotton, hemp, regenerated cellulose fiber or the like. These fibrous liquid-absorbing sheet members are common in that they are formed from a cellulose component. In general, cellulose is hydrophilic because it contains many hydroxyl groups in the molecule. Thus, this good hydrophilicity is utilized for liquid absorption.

In addition, the basis weight of the fibrous urine absorbing sheet member 12 is 10 g / m ² or more, and a preferable basis weight is about 10 to 30 g / m ² . As the basis weight increases, the fiber amount of the fibrous urine absorbing sheet member 12 increases. As a result of the water retention action of the fibrous urine absorbing sheet member 12, the amount of drug-containing urine absorbed by the drug-containing urine absorption layer 10a generally increases. As a result, the drug molecule of the anticancer drug in the drug-containing urine absorbed and held in the drug-containing urine absorption layer 10 a is adsorbed by the activated carbon contained in the activated carbon-containing sheet member 11.

  The vertical relationship between the activated carbon-containing sheet-like member 11 and the fibrous urine-absorbing sheet member 12 constituting the drug-containing urine absorbing layer portion 10a of the anticancer agent-containing urine adsorbing sheet body 1A is in principle free. In any case, the drug-containing urine absorption layer part 10a itself is sandwiched between the drug-containing urine permeation part 20 and the permeation prevention part 30 and is not exposed. Therefore, if the drug-containing urine is absorbed by the drug-containing urine absorbing layer 10a, the external diffusion of drug molecules of the anticancer drug from the anticancer drug-containing urine adsorbing sheet body is greatly reduced.

  According to the disclosure of the cross-sectional view of FIG. 1, the activated carbon-containing sheet-like member 11 is disposed on the first surface 18 side of the drug-containing urine absorption layer portion 10a, and the fibrous urine-absorbing sheet member 12 is formed on the drug-containing urine absorption layer portion 10a. It is arranged on the second surface 19 side. According to the upper and lower arrangements, the drug molecule of the anticancer agent contained in the drug-containing urine that has passed through the drug-containing urine permeation part 20 of the anticancer agent-containing urine adsorbent sheet body 1A is the drug-containing urine absorption layer first. It is adsorbed by the activated carbon of the activated carbon-containing sheet-like member 11 of the part 10a. In addition, the activated carbon-containing sheet-like member 11 is impregnated with the drug-containing urine. Furthermore, the moisture or the like of the drug-containing urine that has not been absorbed by the drug-containing urine absorption layer 10a is absorbed by the fibrous urine absorbing sheet member 12 directly below. In this way, measures for absorption of drug-containing urine are double. In particular, the activated carbon-containing sheet-like member 11 is first easily brought into contact with drug molecules of the anticancer agent, and the adsorption (collection) effect by the activated carbon is further enhanced.

<Drug-containing urine transmission part>
The role of the drug-containing urine permeation part 20 arranged on the first surface 18 side of the drug-containing urine absorption layer part 10a is in addition to protecting the drug-containing urine absorption layer part 10a, and dropping and adhering to the drug-containing urine absorption sheet body The drug-containing urine is allowed to permeate as far as possible to the drug-containing urine absorption layer portion 10a without being excessively absorbed at the stage of the drug-containing urine permeation portion 20.

  Absorbing the drug-containing urine by the drug-containing urine permeation part 20 at the stage of the drug-containing urine permeation part 20 seems to have no problem at first glance. However, the drug molecules in the drug-containing urine are not adsorbed only by the drug-containing urine permeation part 20 and only absorb the drug-containing urine. Then, the drug molecules of the anticancer drug remaining in the drug-containing urine permeation part 20 are likely to adhere to footwear (slippers, sandals, etc.) that are in contact with the drug-containing urine permeation part 20 and the skin of others. And contamination may spread through these. Alternatively, after the drug-containing urine is dried, drug molecules of the anticancer drug are easily exposed on the surface of the drug-containing urine permeation part 20. In this case, it becomes more difficult to capture drug molecules, which is considered a safety issue. Therefore, the characteristic required for the drug-containing urine permeation part 20 is not to absorb and retain the drug-containing urine, but to appropriately permeate the drug-containing urine and promote absorption in the drug-containing urine absorption layer part 10a. Drug molecules are adsorbed by the activated carbon. As a result, the exposure of the drug molecules at the surface 28 portion of the drug-containing urine permeation part 20 is suppressed as much as possible, and the safety of the drug-containing urine absorbent sheet body is enhanced by the containment action.

  Therefore, it is formed from a material (hydrophobic material) having relatively low or poor liquid absorbency (water absorption) as compared with the drug-containing urine absorption layer portion 10a. Therefore, the medicine-containing urine transmission part 20 is formed from a cloth-like member made of resin fibers. The resin fiber cloth-like member is a synthetic resin fiber woven fabric or a synthetic resin fiber nonwoven fabric in consideration of suppression of liquid absorption. Synthetic resin fibers are easily procured resin materials such as polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), or polyethylene terephthalate (PET). Of course, other resin materials such as polylactic acid may be used. The selection of the form of the woven fabric or the nonwoven fabric is arbitrary. During the trial of the example, the basis weight (density) of the nonwoven fabric-like member was lower than that of the woven fabric, so the nonwoven fabric was selected.

  The ability of the drug-containing urine permeation part 20 to permeate the drug-containing urine is evaluated through the test item of 6.9.2 water retention rate from the 6.9 water absorption of “General Nonwoven Fabric Test Method” in accordance with JIS L 1913 (2010). can do. In the test of the same standard, the water retention rate is preferably 500% or less, and more preferably 250% or less. When the water retention rate exceeds 500%, the retention amount of the drug-containing urine in the drug-containing urine permeation part 20 is increased, which is contrary to desired permeation. In addition, as a factor that the water retention rate does not become 0%, the drug-containing urine permeation part 20 itself is a woven fabric or a non-woven fabric and is fibrous. Therefore, some internal residuals cannot be eliminated due to the influence of the surface tension of the drug-containing urine.

<Transmission prevention part>
In addition to protecting the drug-containing urine absorption layer 10a, the role of the permeation prevention unit 30 disposed on the second surface 19 side of the drug-containing urine absorption layer 10a is a drug-containing urine absorbing sheet body (urine absorption sheet member). The drug-containing urine adhering to the water is permeated as it is and received by the permeation preventing unit 30 without leaking outside. That is, leakage of the drug-containing urine from the drug-containing urine absorbent sheet body is prevented.

  Therefore, the permeation preventing unit 30 is formed of a resin sheet member for the purpose of moisture impermeability. The permeation prevention unit 30 includes a resin film. The resin sheet member is formed from a resin that is easily procured, such as polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), or polyethylene terephthalate (PET), from the viewpoint of waterproofness. In addition, other resin materials such as polylactic acid are also added. The resin sheet member has a generally available layer thickness, and is manufactured by a known film forming method such as uniaxial stretching, biaxial stretching, or non-stretching.

  The mutual fixing method of the drug-containing urine permeation part 20 and the permeation prevention part 30 that sandwich the drug-containing urine absorption layer part 10a from above and below is not particularly limited. 1, the drug-containing urine permeation part 20 and the permeation prevention part 30 are adhered to each other by a method such as hot melt (thermal melting of the permeation prevention part 30) in addition to the adhesive. The drug-containing urine absorption layer 10a is fixed. Examples of the adhesive include epoxy resins, acrylate resins, and various resins such as ethylene vinyl acetate resin. In hot melt, a fixing device using a hot platen, a fixing device using ultrasonic vibration, or the like is used. In addition, it can be fixed by sewing.

[Second Embodiment]
The cross-sectional view (schematic diagram) of FIG. 2 shows an anticancer agent-containing urine adsorbing sheet body 1B of the second embodiment. In the anticancer agent-containing urine adsorption sheet 1B of the second embodiment, the drug-containing urine absorption layer 10b placed at the center of the sheet includes an activated carbon-containing sheet member 11, a water-swellable resin member 13, and fibers. A liquid-absorbing sheet member 12 is provided. The urine absorption sheet body 1S which is the main body portion of the anticancer agent-containing urine adsorption sheet body 1B is also a laminate including three layers of the drug-containing urine permeation part 20, the drug-containing urine absorption layer part 10b, and the permeation prevention part 30. Formed as a structure. The drug-containing urine permeation part 20, the permeation prevention part 30, and the fibrous liquid-absorbing sheet member 12 sandwiching the drug-containing urine absorption layer part 10b from above and below are the same as described in the first embodiment.

  In the anticancer agent-containing urine adsorption sheet body 1B, the water-swellable resin member 13 is added to the activated carbon-containing sheet-like member 11 and the fibrous liquid-absorbing sheet member 12, so that the liquid-absorbing ability is further reinforced. Then, when there is a large amount of drug-containing urine that scatters and adheres on the anticancer agent-containing urine adsorption sheet body 1B, the drug-containing urine that cannot be absorbed by the activated carbon-containing sheet member 11 is the fibrous liquid-absorbing sheet member 12. And absorbed in the water-swellable resin member 13. As a result, the safety of the anticancer agent-containing urine adsorption sheet body 1B is further increased.

  In the anticancer agent-containing urine adsorbent sheet 1B, the water-swellable resin member 13 included in the drug-containing urine absorption layer 10b is a commonly used water-absorbing material (water-absorbing polymer). For example, it is a polymer resin material such as a crosslinked product of carboxymethyl cellulose and a crosslinked product of polyacrylate polymer (sodium polyacrylate). The water-swellable resin member 13 is processed in the form of a sheet (including woven fabric and non-woven fabric), beads (granular), and powder, and placed in the drug-containing urine absorption layer 10b. Is done.

  In principle, the vertical relationship of the activated carbon-containing sheet-like member 11, the fibrous liquid-absorbing sheet member 12, and the water-swellable resin member 13 constituting the drug-containing urine absorbing layer portion 10b of the anticancer agent-containing urine adsorbing sheet body 1B is also free. . The drug-containing urine absorption layer 10b itself is sandwiched between the drug-containing urine permeation part 20 and the permeation prevention part 30 in any order, and is not exposed. Therefore, if the drug-containing urine is absorbed by the drug-containing urine absorption layer 10b, the external diffusion of drug molecules of the anticancer drug is greatly reduced.

  According to the disclosure of the cross-sectional view of FIG. 2, the activated carbon-containing sheet-like member 11 is disposed on the first surface 18 side of the drug-containing urine absorption layer portion 10b, and the fibrous liquid-absorbing sheet member 12 is formed on the drug-containing urine absorption layer portion 10b. It is arranged on the second surface 19 side. The water-swellable resin member 13 is provided between the activated carbon-containing sheet-like member 11 and the fibrous liquid-absorbing sheet member 12. According to the arrangement relationship, the drug molecule of the anticancer drug contained in the drug-containing urine that has passed through the drug-containing urine permeation part 20 of the anticancer drug-containing urine adsorbent sheet 1B is the drug-containing urine absorption layer part first. It is adsorbed by the adsorbed activated carbon of the activated carbon-containing sheet-like member 11 of 10b. In addition, the activated carbon-containing sheet-like member 11 is impregnated with the drug-containing urine. Furthermore, the water or the like of the drug-containing urine that has not been absorbed by the drug-containing urine absorption layer 10b is absorbed by the water-swellable resin member 13 and the fibrous liquid-absorbing sheet member 12 directly below. Thus, the absorption measures for drug-containing urine are triple and more sophisticated. In particular, the activated carbon-containing sheet-like member 11 is first easily brought into contact with drug molecules of the anticancer agent, and the adsorption (collection) effect by the activated carbon is further enhanced.

  In addition, the water-swellable resin member 13 has an irregular shape such as a bead shape in addition to the sheet shape. Therefore, for stable holding, the arrangement between the activated carbon-containing sheet-like member 11 and the fibrous liquid-absorbing sheet member 12 is suitable.

[Fixed]
The anticancer agent-containing urine adsorbing sheet 1A (see FIG. 1) of the anticancer agent-containing urine adsorbing sheet 1A of the first embodiment described so far and the anticancer agent-containing urine adsorbing sheet 1B of the second embodiment ( The drug-containing urine absorption layer portion 10b (see FIG. 2) has a structure that is obviously laminated. When the members of each layer of the drug-containing urine absorption layer are separated from each other, there are more gaps between the layers, and the absorption performance when the drug-containing urine permeates the drug-containing urine permeation part and reaches the drug-containing urine absorption layer part May decrease. That is, the water absorption speed decreases. Moreover, the anticancer agent-containing urine adsorbent sheet itself is thick, which is not preferable in terms of folding and storage efficiency. Considering these points, the members of the respective layers of the drug-containing urine absorption layer are appropriately joined. In joining the members, a method such as fixing with an adhesive or crimping by embossing is used.

  Furthermore, in the anticancer agent-containing urine adsorbing sheet bodies 1A and 1B of the respective embodiments, the drug-containing urine absorption layer portion 10a or 10b and the drug-containing urine permeation portion 20 arranged on the first surface side thereof also contain the same drug. The urine absorbing layer portion 10a or 10b and the permeation preventing portion 30 disposed on the second surface side thereof are also joined. This is also due to the effect of reducing the gap for each member or reducing the overall thickness.

  The bonding between the drug-containing urine absorption layer portion 10a or 10b and the drug-containing urine permeation portion 20 is fixation by an adhesive, pressure bonding by embossing, hot melt, or the like. If the drug-containing urine permeation part is a cloth-like member made of synthetic resin fibers, heat fusion is easy. In this joining, it is not a single surface, but is fixed to each other in the form of dots or lines spaced apart from each other. An adhesive is exclusively used for joining the drug-containing urine absorption layer part 10a or 10b and the permeation prevention part 30. The significance of the permeation prevention unit is to prevent leakage of drug-containing urine containing drug molecules of the anticancer drug dripped onto the anticancer drug-containing urine adsorbing sheet. Therefore, since it is necessary to improve waterproofness, a joining method in which a hole or a crack is generated in the permeation preventive part cannot be adopted. For this reason, it becomes fixing with an adhesive from a safety aspect. Also in this joining, it is not a single surface, but is fixed to each other in the form of dots or lines spaced apart.

  Therefore, in the anticancer agent-containing urine adsorption sheet body 1A (see FIG. 1) of the first embodiment and the anticancer agent-containing urine adsorption sheet body 1B (see FIG. 2) of the second embodiment, the drug-containing urine permeation is performed. The thickness when the portion 20, the drug-containing urine absorption layer portion 10a or 10b, and the permeation prevention portion 30 are laminated and fixed is in the range of 0.3 to 5 mm, preferably 0.3 to 3 mm, More preferably, it is in the range of 0.3 to 1.5 mm. The thickness of the anticancer agent-containing urine adsorption sheet body corresponds to the entire thickness of the anticancer agent-containing urine adsorption sheet body 1A, 1B. As disclosed in the measurement of Examples described later, the thickness of the anticancer agent-containing urine adsorbent sheet body is a numerical value of the thickness when it becomes dense by compression.

  The range of the thickness is a thickness considering an actual arrangement around the toilet bowl. As the thickness increases, the drug molecule adsorption performance, the liquid absorption performance as a sheet body, and the strength of the sheet increase. However, a step with the floor is generated around the toilet bowl due to the thickness of the suction sheet body itself. If it does so, there exists a possibility that a patient may trip over and fall by an adsorption sheet body. In particular, elderly patients, patients whose leg strength has been weakened by hospitalization, and patients who have pressed an infusion stand are likely to fall over when moving before and after excretion. Therefore, it is necessary to thin the thickness of the anticancer agent-containing urine adsorbing sheet to reduce the level difference from the floor surface. In addition, although it is preferable that the lower limit is thinner, approximately 0.3 mm is required in consideration of the adsorption performance of drug molecules, the liquid absorption performance as a sheet, and the strength during handling.

[Placement / Installation]
Anticancer agent-containing urine adsorption sheet body 1A (urine absorption sheet body 1S) of the first embodiment (see FIG. 1) and anticancer agent-containing urine adsorption sheet body 1B (urine of the second embodiment (see FIG. 2)) When arranging the absorbent sheet body 1S) around the toilet bowl, it is necessary to efficiently fix the absorbent sheet body 1S to the floor or wall surface to prevent displacement. Therefore, as shown in FIGS. 1 and 2, a non-slip portion 50 is further provided on the back surface of the permeation prevention portion 30. The illustrated anti-slip portion 50 is an example of a double-sided tape. It is formed of an adhesive portion 51 and a protective sheet 52 that are the main body of the tape, and is attached to the back surface of the permeation prevention portion 30. At the time of use, the protective sheet 52 is peeled off, the adhesive portion 51 is adhered to the floor surface or wall surface around the toilet bowl, and the anticancer agent-containing urine adsorption sheet body 1A or 1B is arranged around the toilet bowl. As the non-slip portion 50, an elastomer resin having viscoelasticity may be applied to the back surface of the permeation prevention portion 30 to increase the frictional force and improve the fixing performance (not shown). Furthermore, a hook-and-loop fastener or the like may be used as the anti-slip portion 50 (not shown).

  The inventors determined whether the properties and physical properties of the anti-cancer agent-containing urine adsorbing sheet were divided into main constituent members. Then, an anticancer agent-containing urine adsorbent sheet was used as an agent for preparation of an actual anticancer agent, and an evaluation was attempted.

[Performance evaluation and selection of drug-containing urine permeation section]
A preferable characteristic of the member used for the drug-containing urine permeation part is to pass (permeate) the dripped drug-containing urine as much as possible while suppressing absorption of the drug-containing urine in the drug-containing urine permeation part. Therefore, JIS L 1913 (2010): General nonwoven fabric test method, 6.9 water absorption (JIS method), 6.9.2 (water retention) was adopted. In accordance with this standard, the following eight kinds of cloth-like members 1 to 8 were prepared and subjected to the general nonwoven fabric test. While measuring the water retention rate (%) of each cloth-like member, the performance was evaluated.

  Each cloth-like member was cut into a square having a side of 50 mm, and the weight was measured (in units of 1 mg). The cut cloth-like member was immersed in a vat filled with ion-exchanged water for 15 minutes. After soaking, the cloth-like member was taken out of the vat and waited for one minute for water to drip. And this weight was measured (1 mg unit). The water retention rate was determined from the weight difference before and after the cloth member was immersed in water. Three articles (n = 3) were measured for one cloth-like member, and the arithmetic average value was defined as the water retention rate (%) of the cloth-like member.

<Cloth-like member>
Cloth-like member 1: manufactured by Hirose Paper Co., Ltd., 05TH-24, material: polyethylene terephthalate, form: non-woven fabric, basis weight 25.6 g / m ² .
Cloth-like member 2: manufactured by Hirose Paper Co., Ltd., 05EP-26, material: polyethylene terephthalate and polypropylene, form: non-woven fabric, basis weight 26.4 g / m ² .
Cloth-like member 3: manufactured by Shinwa Co., Ltd., 9716-F0, material: polyethylene terephthalate and polyethylene, form: non-woven fabric, basis weight 16.0 g / m ² .
Cloth-like member 4: manufactured by Uma Paper Co., Ltd., UL-S, material: polypropylene and polyethylene, form: non-woven fabric, basis weight 18.0 g / m ² .
Cloth-like member 5: manufactured by Hirose Paper Co., Ltd., 05EP-23, material: polyethylene terephthalate and polypropylene, form: non-woven fabric, basis weight 23.4 g / m ² .
Cloth-like member 6: manufactured by Hirose Paper Co., Ltd., 05EP-35, material: polyethylene terephthalate and polypropylene, form: non-woven fabric, basis weight 35.4 g / m ² .
Cloth-like member 7: manufactured by Futamura Chemical Co., Ltd., TCF # 8022, material: rayon, form: non-woven fabric, basis weight 22.0 g / m ² .
Cloth-like member 8: manufactured by Marusan Industry Co., Ltd., I / CXX25- # 25-330, material: cotton, form: non-woven fabric, basis weight 25.0 g / m ² .

The results are shown in Table 1. In Table 1, the material PET represents polyethylene terephthalate, PE represents polyethylene, and PP represents polypropylene. In order from the top, the form, material, basis weight (g / m ² ), water retention (%), and quality evaluation were set. In the pass / fail evaluation, a water retention rate of less than 500% was designated as “A”, and 500% or more was designated as “F”. If the water retention rate is less than 500%, it is almost impossible to feel dampness when touched with bare hands.

<Consideration of water retention rate>
Although the cloth-like members 1 to 6 formed of the synthetic resin fiber material had variations, the water retention rate was generally low. On the other hand, in the rayon (cellulose origin) and cotton (cellulose) cloth-like members 7 and 8, the water retention rate increased. Although the cloth-like member of the synthetic resin fiber is affected by the surface tension, it can be considered that the water absorption of the cloth-like member itself is suppressed due to the hydrophobic property. Therefore, it is preferable to employ a cloth-like member (nonwoven fabric) made of resin fibers, particularly synthetic resin fibers, in configuring the drug-containing urine permeation part.

<Consideration of water retention rate>
Although the cloth-like members 1 to 6 formed of the synthetic resin fiber material had variations, the water retention rate was generally low. On the other hand, in the rayon (cellulose origin) and cotton (cellulose) cloth-like members 7 and 8, the water retention rate increased. Although the cloth-like member of the synthetic resin fiber is affected by the surface tension, it can be considered that the water absorption of the cloth-like member itself is suppressed due to the hydrophobic property. Accordingly, it is preferable to employ a cloth-like member (nonwoven fabric) made of resin fibers, particularly synthetic resin fibers, in configuring the drug solution permeation portion.

[Performance evaluation and selection of adsorbed activated carbon]
The adsorption main body of the drug molecule of the anticancer agent in the anticancer agent adsorption sheet is adsorbed activated carbon. Therefore, the adsorbing ability of molecules was evaluated for 8 kinds of adsorbed activated carbons 1 to 8 and 9 kinds of adsorbing materials in total including synthetic zeolite. However, anticancer drugs are expensive, and handling is necessary due to toxicity and other problems. Therefore, in evaluating the adsorption performance, the adsorption ability of activated carbon was measured using a compound similar to the drug molecule of the currently prescribed anticancer drug as a substitute substance.

<Adsorption material>
As the adsorbed activated carbons 1 to 8, activated carbon manufactured by Futamura Chemical Co., Ltd. was used.
Adsorbed activated carbon 1: Powdered activated carbon “S” (woody)
Adsorbed activated carbon 2: Powdered activated carbon “IP” (woody)
Adsorbed activated carbon 3: Powdered activated carbon “CI” (coconut shell)
Adsorbed activated carbon 4: Powdered activated carbon “CB” (coconut shell)
Adsorbed activated carbon 5: Powdered activated carbon “GB” (coal-based)
Adsorbed activated carbon 6: Granular activated carbon “CN480S” (coconut shell)
Adsorbed activated carbon 7: Granular activated carbon “CW480AL” (coconut shell)
Adsorbed activated carbon 8: Fibrous activated carbon “ACF” (phenolic resin)

Details of physical properties are shown in Table 2. As a control for the activated carbon, a synthetic zeolite “Zeoram F-9, manufactured by Tosoh Corporation” was used.
In addition, about adsorption | suction activated carbon 6, 7, and 8, it grind | pulverized to the average particle diameter of about 15 micrometers with the sample mill, and used for the subsequent tests.

<Measurement of physical properties of adsorbed activated carbon>
The average particle diameter (μm) was measured using a Shimadzu Corporation laser diffraction particle size distribution analyzer “SALD-3000”. The “average particle diameter” in this measurement means the particle diameter (cumulative average diameter) at an integrated value of 50% in the particle size distribution obtained by the laser diffraction / scattering method using the same apparatus.

For the average pore diameter and the pore volume (V _D ) of the DH plot, an automatic specific surface area / pore distribution measuring device “BELSORP-miniII” manufactured by Microtrack Bell Co., Ltd. was used. The total pore volume (cm ³ / g (or cc / g)) with a pore diameter in the range of 1 nm to 100 nm was measured using the same apparatus, applying Gurvitsch's law and applying nitrogen adsorption at a relative pressure of 0.953 by the DH method. The amount (V) was calculated by converting into the volume (V _p ) of liquid nitrogen by the following mathematical formula (i).

In formula (i), M _g is the molecular weight of the adsorbate (nitrogen: 28.020), and ρ _g (g / cm ³ ) is the density of the adsorbate (nitrogen: 0.808).

The average pore diameter (nm) is calculated by using the pore volume (cc / g) and specific surface area (m ² / g) values obtained from the above-mentioned measurement, assuming that the pore shape is cylindrical. Obtained from ii).

<Substitute substance>
Representing low molecular weight (for example, cyclophosphamide (molecular weight: 279.10) and the like), caffeine “molecular formula: C ₈ H ₁₀ N ₄ O ₂ , molecular weight: 194.19 (manufactured by Kishida Scientific Co., Ltd., anhydrous cafe) In) ”.
Representing medium molecular weight (for example, mitomycin (molecular weight: 334.33) etc.), quinine “molecular formula: C ₂₀ H ₂₄ N ₂ O ₂ , molecular weight: 324.42 (manufactured by Kanto Chemical Co., Inc., quinine sulfate dihydrate) Used).
Hematoporphyrin “molecular formula: C ₃₄ H ₃₈ N ₄ O ₆ , molecular weight: 598.69 (manufactured by Wako Pure Chemical Industries, Ltd., hematoporphyrin)” on behalf of high molecular weight (for example, irinotecan (molecular weight: 67.718) etc.) It was used.
These three types of alkaloid substitutes have molecular weights approximately similar to drug molecules (medicinal ingredients) of anticancer agents. For this reason, the behavior of activated carbon adsorption was estimated to be approximate and adopted.

<Preparation of test solution for substitute substance>
100 mg of the above anhydrous caffeine was dissolved in 1 L of ion-exchanged water to prepare a caffeine aqueous solution (pH: 7.2).
The quinine sulfate dihydrate 120.7 mg was dissolved in 1 L of ion-exchanged water to prepare an aqueous quinine solution (pH: 6.8).
The above hematoporphyrin (117.65 mg) was dissolved in 100 mL of ethanol, and ion exchange water was added to the ethanol solution to make a total volume of 1 L to prepare a hematoporphyrin aqueous solution (pH 5.1).

<Test and evaluation method (test solution)>
25 mg of each adsorbing material was weighed and put into a 100 mL Erlenmeyer flask. Into this Erlenmeyer flask, 50 mL of an aqueous caffeine solution, 50 mL of an aqueous quinine solution, or 50 mL of an aqueous hematoporphyrin solution was injected according to the test solution of the substitute substance to be measured. At the time of one adsorption measurement, the test liquid of the substitute substance that enters the Erlenmeyer flask was one kind. That is, the test solution of two kinds of substitute substances never enters the Erlenmeyer flask at a time.

  After injecting 50 mL of the test solution of the substitute substance into the Erlenmeyer flask (100 mL) containing the adsorbing material (25 mg), the Erlenmeyer flask was shaken for 60 minutes. The solution after shaking was suction filtered through a 0.45 μm membrane filter to obtain a filtrate for each test solution of each adsorbent material. For caffeine and quinine, the TOC concentration in the filtrate was measured using a TOC meter (manufactured by Shimadzu Corporation, TOC-V). It was. For hematoporphyrin, the absorbance of the filtrate was measured using a spectrophotometer (manufactured by Shimadzu Corporation, UVmini-1240), and the amount of decrease in absorbance was compared with the amount of adsorption by the adsorbing material compared to the initial aqueous solution. did. In addition, it measured twice about one adsorbent material (n = 2), and calculated | required the arithmetic average.

The adsorption rate (%) was determined as “{(initial concentration of test solution) − (concentration of filtrate after filtration)} / (initial concentration of test solution) × 100”. The results are Tables 2 and 3. For each adsorbent material, morphology, raw material origin, average particle diameter (μm), average pore diameter (nm), pore volume (V _D ) (cm ³ / g) by DH plot method, caffeine adsorption rate ( %), Quinine adsorption rate (%), hematoporphyrin adsorption rate (%), and overall evaluation (A, B, or F). In the comprehensive evaluation, an adsorbing material in which the adsorption rates of the three types of substitute substances were all 50% or more was evaluated as “A”. The adsorbing material in which the adsorption rate of the three types of substitute substances was 50% or more for two types was evaluated as “B”. The evaluation was “F”.

<Evaluation with artificial urine>
Furthermore, the adsorption ability of activated carbon for the solution prepared by dissolving the above-mentioned anhydrous caffeine and hematoporphyrin in artificial urine for the above-mentioned five kinds of adsorption activated carbons, 1, 3, 4, 5, and 8. Was measured. The amount of salt differs between water and artificial urine. Therefore, it is for the purpose of verifying it closer to the actual urine. The physical properties of each activated carbon are measured as described above. In addition, although it is the same activated carbon, the reason which the physical-property value was different considers the difference in a measurement day, and the dispersion | variation in a measuring object.

The artificial urine was prepared in accordance with the formulation of “A.2.1 Artificial urine” described in JIS T3214 (2011) bladder (bladder) indwelling catheter, Annex A.
100 mg of the above anhydrous caffeine was dissolved in 1 L of artificial urine to prepare artificial urine containing caffeine as a substitute substance.
After 117.65 mg of the above hematoporphyrin was dissolved in 100 mL of ethanol, artificial urine containing hematoporphyrin as a substitute substance was prepared by adding artificial urine to the ethanol solution to make a total volume of 1 L.

<Test and evaluation method (artificial urine)>
For anhydrous caffeine, 25 mg of each adsorbent material was weighed and put into a 100 mL Erlenmeyer flask. About hematoporphyrin, 100 mg of each adsorbing material was weighed and put into a 100 mL Erlenmeyer flask. Into this Erlenmeyer flask, 50 mL of artificial urine of the substitute substance was injected according to the test solution of the substitute substance to be measured, and the Erlenmeyer flask was shaken for 60 minutes. The solution after shaking was suction filtered through a 0.45 μm membrane filter to obtain a filtrate for each artificial urine of each adsorbent material.
About anhydrous caffeine, it measured using HPLC (made by Shimadzu Corporation, LC-20AD) and column CAPCELLPAK C18MG, (phi) 3.0 mm x 150 mm, 5 micrometers (made by Shiseido). The concentration was calculated from the peak area of HPLC.
For hematoporphyrin, the absorbance of the filtrate was measured using the spectrophotometer described above, and the amount of decrease in the absorbance was taken as the amount adsorbed by the adsorbing material compared to the original artificial urine. In addition, it measured twice about one adsorbent material (n = 2), and calculated | required the arithmetic average.

The adsorption rate (%) of the substitute substance artificial urine was also determined as “{(initial concentration of test solution) − (concentration of filtrate after filtration)} / (initial concentration of test solution) × 100”. The results are in Table 4. For each adsorbent material, morphology, raw material origin, average particle diameter (μm), average pore diameter (nm), pore volume (V _D ) (cm ³ / g) by DH plot method, substitute substance (caffeine) ) Adsorption rate (artificial urine evaluation) (%), substitute substance (hematoporphyrin) adsorption rate (artificial urine evaluation) (%), and comprehensive evaluation (A, B, or F). In the comprehensive evaluation, an adsorbing material in which the adsorption rates of the two types of substitute substances were both 60% or more was evaluated as “A”. An adsorption material that was in the range of 30% to 60% of the adsorption rates of the two substitute substances was evaluated as “B”, and one of the adsorption rates of the two substitute substances was less than 30%. The adsorbed material that was present was evaluated as “F”.

<Consideration of adsorption rate (test solution)>
Synthetic zeolite hardly exhibited an adsorption effect in the experimental system. The advantage of activated carbon became clear from the comparison. Therefore, when the adsorbed activated carbons 1 to 8 are viewed, the adsorption of low molecular weight molecules typified by caffeine is generally good. However, the adsorption rate decreases as the molecular weight increases, such as quinine and hematoporphyrin.

  Considering this point, the first difference is the average pore diameter. That is, the adsorbed activated carbons 1 to 5 have an average pore diameter of 1.7 nm or more. However, the adsorbed activated carbon 6-8 is less than 1.7 nm. Then, an average pore diameter of 1.7 nm or more can be an effective classification index for evaluating adsorption performance. The upper limit of the average pore diameter is considered to be approximately 5 nm from the adsorbed activated carbon 1 in view of the result of the physical property measurement.

To improve the adsorption efficiency of molecules with a wide range of molecular weights, a second pore volume can be added by the DH plot method. That is, the adsorbed activated carbons 1 to 5 have a pore volume (at a pore diameter of 1 to 100 nm) of 0.08 cm ³ / g or more. However, the adsorbed activated carbons 6 to 8 are less than 0.08 cm ³ / g. Then, a pore volume of 0.08 cm ³ / g or more can be an effective classification index for evaluating adsorption performance in addition to the average pore diameter. In addition, the upper limit of the pore volume by the DH plot method is considered to be approximately 2 cm ³ / g from the adsorption activated carbon 1 in view of the result of the physical property measurement.

  From this result, activated carbon is superior for efficiently adsorbing a wide range of molecular weight molecules. Even in the activated carbon, there are variations in the molecular weight of the adsorption target. Therefore, the performance of activated carbon can be selected by adding an index of average pore diameter and further an index of pore volume (range of pore diameter of 1 to 100 nm) by DH plot method. Then, the adsorption efficiency of molecules having a wide molecular weight can be further increased.

<Consideration of adsorption rate (artificial urine)>
Taking into account the results of artificial urine of the substitute substances (caffeine and hematoporphyrin) in Table 4, it was confirmed that the results of ion-exchanged water and the results of artificial urine had the same tendency. Therefore, activated carbon is effective evidence for the adsorption of drug molecules in urine actually excreted from patients. Moreover, from the adsorption | suction activated carbon 8 and the result other than that, the influence of the parameter | index of the pore volume by DH plot method was able to be confirmed similarly.

[Performance evaluation and selection by using anticancer drugs]
Based on the results of performance evaluation using the substitute substance described above and evaluation by artificial urine, the adsorption performance of the anticancer agent by the adsorbent material was actually verified. As anticancer agents, 5-fluorouracil (manufactured by Kyowa Hakko Kirin Co., Ltd., 5-FU injection 250 mg), cyclophosphamide (manufactured by Shionogi Pharmaceutical Co., Ltd., Endoxan (registered trademark) 500 mg for injection), methotrexate (Pfizer Inc.) Three types of company, Methotrexate (registered trademark) intravenous drip infusion 200 mg) were prepared. In preparation of the concentration of the anticancer agent, 5-fluorouracil was used as a test solution at a concentration of 1 mg / mL, cyclophosphamide was used as 1 mg / mL, and methotrexate was used as a test solution at a concentration of 1 mg / mL.

<Anticancer drug adsorption test and evaluation method>
The above-mentioned “adsorbed activated carbon 1 (woody)”, “adsorbed activated carbon 3 (coconut shell)”, and “synthetic zeolite” were used as adsorbing materials. 1.25 g of each adsorbing material was weighed and put into a 100 mL Erlenmeyer flask. Into this Erlenmeyer flask, a test solution of 50 mL of 5-fluorouracil aqueous solution, 50 mL of cyclophosphamide aqueous solution, or 50 mL of methotrexate aqueous solution was injected. At the time of one adsorption measurement, the test solution of the anticancer agent which enters an Erlenmeyer flask was made into one kind. That is, two types of anticancer agents never enter the Erlenmeyer flask at a time.

  50 mL of anticancer drug test solution was injected into an Erlenmeyer flask (100 mL) containing an adsorbing material (1.25 g), and then the Erlenmeyer flask was shaken for 60 minutes. The solution after shaking was suction filtered through a 0.45 μm membrane filter to obtain a filtrate for each test solution of each adsorbent material. Next, the filtrate was measured by HPLC (manufactured by Hitachi High-Technologies Corporation, L-2000 series). For the analysis of the above three kinds of anticancer agents, Shodex (registered trademark) C18P4E, a column having a thickness of 5 μm, an inner diameter of 4.6 mm, and a length of 250 mm (made by Showa Denko KK) was used. In addition, an example in which the adsorbent material was not added and only the anticancer drug test solution was injected was defined as a control group (blank), and the peak area during HPLC analysis of the control group was defined as 100%. Subsequently, the peak area of each sample was calculated, and the concentration of the anticancer agent of each sample was calculated from the area ratio. In addition, it measured 5 times per sample and made it the arithmetic mean.

The adsorption rate (%) is “{(solution concentration when no adsorbing material is charged) − (solution concentration after adsorbing material is charged and adsorbed)} / (no adsorbing material is charged) Solution concentration) × 100 ”. The results are in Table 5. For each adsorbent material, morphology, raw material origin, average particle diameter (μm), average pore diameter (nm), pore volume (V _D ) by DH plot method (cm ³ / g), 5-fluorouracil adsorption rate (%), Cyclophosphamide adsorption rate (%), methotrexate adsorption rate (%), and comprehensive evaluation (three stages of A, B, or F) are described. In the comprehensive evaluation, an adsorbent material in which the adsorption rates of the three types of anticancer agents were all 50% or more was evaluated as “A”. The adsorbing material that had 50% or more adsorption rate of 3 types of anticancer agents was evaluated as “B”, and the adsorption rate of 3 types of anticancer agents was less than 50% in 2 types. The adsorption material was evaluated as “F”.

<Consideration of adsorption rate by using anticancer agent>
As a result of the performance evaluation using the anticancer agent, the synthetic zeolite hardly exhibited the adsorption effect as in the evaluation of the substitute substance. On the other hand, in the example of activated carbon, the favorable adsorption effect was confirmed about any anticancer agent. Here, three types of anticancer agents used have different molecular weights. For each anticancer agent, the activated carbon exhibited sufficient adsorption performance. Therefore, the adsorption effect of the anticancer agent by activated carbon is extremely high. Moreover, the correlation with the evaluation by a substitute substance was also able to be confirmed.

[Preparation of anticancer drug-containing urine adsorbent sheet]
Based on the performance evaluation results of the adsorbed activated carbon incorporated into the drug-containing urine permeation part and the drug-containing urine absorption layer part, the inventors prepared six types of anticancer drug-containing urine adsorption sheet bodies (Example sheet bodies 1 to 5, And Comparative Example Sheet 1). In the production, the structure of the second embodiment shown in FIG. The drug-containing urine absorption layer portions of the example sheet bodies 1 and 2 were formed by laminating an activated carbon-containing sheet member containing adsorbed activated carbon, a water-swellable resin member, and a fibrous liquid-absorbing sheet member in this order.

  Example sheet bodies 3, 4, and 5 employ the structure of the first embodiment shown in FIG. The drug-containing urine absorption layer portions of the example sheet bodies 3, 4, and 5 were laminated and formed in the order of an activated carbon-containing sheet-like member containing adsorbed activated carbon and a fibrous liquid-absorbing sheet member. In Comparative Example Sheet 1, the drug-containing urine absorption layer portion was only the activated carbon-containing sheet-like member.

<Preparation of Example Sheet 1>
In producing the sheet body 1, the above-mentioned adsorbed activated carbon 3 was adopted as the adsorbed activated carbon of the activated carbon-containing sheet-like member. The adsorbed activated carbon 3 and the crushed softwood pulp were put into a water tank and stirred to obtain a slurry. This slurry-like product was finished into a sheet by paper making procedures and dried (production of activated carbon-containing sheet-like member). The finished activated carbon-containing sheet-shaped member had a basis weight of 25 g / m ² and a content of adsorbed activated carbon of 30%. On the lower layer side of this activated carbon-containing sheet-like member, a granular material of an acrylic acid polymer partial sodium salt crosslinked product (manufactured by Sumitomo Seika Co., Ltd.) is placed as a water-swellable resin member, and a fibrous liquid-absorbing sheet is further provided on the lower layer side. The member was provided with pulverized pulp (manufactured by Weyerhaeuser Company, basis weight 120 g / m ² ). In this way, three types of members were laminated to temporarily prepare a drug-containing urine absorption layer.

  The cloth-like member 4 was used for the drug-containing urine permeation part. The nonwoven fabric of the cloth-like member 4 was placed on the upper side of the temporarily prepared drug-containing urine absorption layer, these members were passed through an embossing roller and compressed (embossing and hot melt bonding), and the members of each layer were bonded together. The pattern at the time of embossing was in the form of parallel vertical stripes with intervals. A synthetic resin sheet made of polyethylene (Fukusuke Kogyo Co., Ltd.) serving as a permeation-preventing part on the lower side of the integrated product-containing urine permeation part and the medicine-containing urine absorption layer part (below the medicine-containing urine absorption layer part). Made, 20 μm thick), and bonded and fixed to each other with an adhesive (Henkel Japan Co., Ltd.). The adhesive was also applied in the form of parallel vertical stripes with intervals. In addition, the drug-containing urine permeation part and the permeation prevention part were enlarged at least 1 cm or more in order to cover the drug-containing urine absorption layer part. The anticancer agent-containing urine adsorbent sheet body in the production is the photograph of FIG. 3, and the average thickness when measuring five points of about 59 cm × 44 cm was about 1.2 mm. The thickness of the sheet was measured using a constant pressure caliper “ABS Digimatic constant pressure caliper NTD25-20CX” manufactured by Mitutoyo Corporation. A double-sided tape serving as a non-slip portion was attached to the back surface of the synthetic resin sheet of the permeation preventive portion. The upper part of FIG. 3 is an overall photograph in which a part of the sheet body is turned upside down, and the lower part is an enlarged photograph of a place where the double-sided tape is attached. In addition, since it is a measurement by a constant pressure caliper, the sheet body has a compressed thickness. Therefore, the measured value is a value that is thinner than the apparent thickness.

<Preparation of Example Sheet Body 2>
When producing the example sheet body 2, the fibrous liquid-absorbing sheet member used for the example sheet body 1 was changed to a basis weight of 60 g / m ² . All other materials and manufacturing methods were the same. The magnitude | size was the same as that of the Example sheet | seat body 1, and the average thickness when arbitrary 5 points | pieces were measured was about 0.8 mm.

<Preparation of Example Sheet Body 3>
In producing the example sheet body 3, the water-swellable resin member used in the example sheet body 1 was omitted. Moreover, the fibrous liquid-absorbing sheet member used for the sheet body 1 was changed to a basis weight of 60 g / m ² . All other materials and manufacturing methods were the same. The magnitude | size was the same as that of the Example sheet | seat body 1, and the average thickness when arbitrary 5 points | pieces were measured was about 0.7 mm.

<Preparation of Example Sheets 4 and 5>
When producing the example sheet body 4, the fibrous liquid-absorbing sheet member used for the example sheet body 3 was changed to a basis weight of 20 g / m ² . All other materials and manufacturing methods were the same. The size was the same as that of the example sheet body 1.
When producing the example sheet body 5, the fibrous liquid-absorbing sheet member used in the example sheet body 3 was changed to a basis weight of 10 g / m ² . All other materials and manufacturing methods were the same. The size was the same as that of the example sheet body 1.
For the example sheet bodies 4 and 5, the average thickness when any five points were measured was about 0.4 mm.

<Preparation of Comparative Example Sheet 1>
In producing the comparative example sheet body 1, the water-swellable resin member and the fibrous liquid-absorbing sheet member used in the example sheet body 1 were omitted. All other materials and manufacturing methods were the same. The magnitude | size was the same as that of the Example sheet | seat body 1, and the average thickness when arbitrary 5 points | pieces were measured was about 0.2 mm.

[Water absorption test]
For measurement of the maximum water absorption rate (mL / s) and the saturated water absorption (L / m ² ), an automatic water absorption measuring device (Larose method) “IT-AL” manufactured by Intec Co., Ltd. was used. And according to the 7.3 surface water absorption method of the water absorption test method of JIS L 1907 (2010) textiles, the maximum water absorption rate (mL / s) and saturation of the example sheet bodies 1 to 5 and the comparative sheet body 1 The water absorption (L / m ² ) was measured. At the time of measurement, each sheet body was cut into a disk shape having a diameter of 60 mm to obtain a test piece. The test piece was placed in the measuring device with the drug-containing urine permeation portion side of the test piece facing the water absorption surface of the measuring device. Based on this standard, the maximum absorption rate was determined from the water absorption amount and the water absorption time. Further, the water absorption amount at the time when the change in the water absorption rate disappeared was defined as the saturated water absorption amount. In view of the performance of the apparatus, the saturated water absorption is 3.50 L / m ² .

Five products (n = 5) were measured for each sheet body, and a simple average was obtained. The results are Tables 6 and 7. In the comprehensive evaluation, a maximum water absorption rate of 0.05 mL / s or more and a saturated water absorption of 0.20 g / m ² or more were evaluated as “A”. When at least one of the conditions was not satisfied, it was judged as an evaluation of “F” not suitable for use.

<Results and discussion of water absorption test>
The absorption target of the anticancer drug-containing urine adsorbent sheet is urine excreted from the patient, and includes urine leaked to the floor around the toilet in addition to scattered matter around the toilet. Then, the higher the urine absorption ability of the anticancer agent-containing urine adsorbent sheet body, the better. Looking at Tables 6 and 7 from this point of view, all of the example sheet bodies 1 to 5 showed good water absorption performance. The difference in the water absorption performance of the example sheet is caused by the presence or absence of the water-swellable resin and the basis weight of the fibrous urine absorbent sheet member. Even if the basis weight of the fibrous urine absorbing sheet member of the example sheet member 4 is 10 g / m ² , the predetermined level is satisfied. Accordingly, the basis weight 10 g / m ² of the fibrous urine absorbing sheet member can be said to be a lower limit value. In particular, the example sheet bodies 1 and 2 had very high performance. From this point, it is preferable from the viewpoint of urine absorption to add the water-swellable resin member to the drug-containing urine absorption layer. The proper use of the example sheet bodies 1 and 23 and the example sheet bodies 4 and 5 depends on the processing ability such as the number of patients. Moreover, if it omits from the comparative example sheet body 1 to the fibrous urine absorbing sheet member, the water absorbing ability is lowered. In this case, assuming an actual use environment, an arrangement place, etc., the capacity is slightly insufficient.

[Anti-cancer drug adsorption test]
The inventors are representative of the three types of prepared anticancer drug-containing urine adsorbent sheet bodies (Example sheet bodies 1, 3 and Comparative sheet body 2) currently prescribed in the clinical practice of chemotherapy. The adsorption capacity was measured using an anticancer agent. The drug molecules of the anticancer drug used in the test were cyclophosphamide (manufactured by Shionogi & Co., Ltd., Endoxan (registered trademark) 500 mg for injection), methotrexate (manufactured by Pfizer Inc., methotrexate (registered trademark) intravenous infusion) Liquid 200 mg) and paclitaxel (manufactured by Bristol-Myers, Taxol (registered trademark) injection solution 30 mg) having three different molecular weights.

In producing “Comparative Example Sheet 2”, the activated carbon-containing sheet-like member containing the adsorbed activated carbon 1 is omitted from the above-mentioned Example sheet 1, and the fibrous liquid-absorbing sheet member is changed to a basis weight of 60 g / m ² . did. All other materials and manufacturing methods were the same. The magnitude | size was the same as that of the Example sheet | seat body 1, and the average thickness when arbitrary 5 points | pieces were measured was about 0.8 mm.

  In preparing the concentration of the anticancer agent, cyclophosphamide was prepared at 20 mg / mL, methotrexate was 6 mg / mL, and paclitaxel was prepared at a concentration of 0.2 mg / mL according to JIS T 3214 (2011). Diluted with urine. The dripping amount of the anticancer agent was calculated from the maximum dose of each anticancer agent and the unchanged urinary excretion rate. In addition, the maximum dose was calculated from the average body weight of Japanese people, and the urinary unchanged versus excretion rate was referred to an interview form. About 1 ml of artificial urine diluted solutions of each anticancer agent, 1 mL was dropped on the drug-containing urine permeation portion of the anticancer agent-containing urine adsorbent sheet. A human having a body weight of about 60 kg puts on a resin bottom (non-penetrating) slipper and stepped on an artificial urine diluted solution of each anticancer drug immediately after dropping for 10 seconds.

  Instead of using an anticancer agent-containing urine adsorbent sheet as a control group for using an anticancer agent-containing urine adsorbent sheet, artificial urine dilutions of each anticancer agent were placed under the same conditions on a smooth stainless steel plate. Then, the slipper was similarly put on and stepped on for 10 seconds.

  Then, it got off from the anticancer agent-containing urine adsorbent sheet, and the back surface of the slipper (the contact surface with the artificial urine diluted solution of the anticancer agent) was wiped with absorbent cotton and 5 mL of purified water. Absorbent cotton and purified water were collected, and the supernatant was collected by centrifugation. The supernatant was measured by HPLC (manufactured by Hitachi High-Technologies Corporation, L-2000 series). For the analysis of the above three kinds of anticancer agents, Shodex (registered trademark) C18P4E, a column having a thickness of 5 μm, an inner diameter of 4.6 mm, and a length of 250 mm (made by Showa Denko KK) was used.

  The peak area at the time of HPLC analysis of the control group (dropped on the stainless steel plate) was defined as 100%. Subsequently, the peak area of each sample was calculated, and the concentration of the anticancer agent of each sample was calculated from the area ratio. Thus, the relative adsorption rates (%) of the three types of anticancer agents were determined for the example sheet bodies 1 and 3 and the comparative example sheet body 2. In addition, the adsorption rate was measured 5 times per sample, and the arithmetic average was taken.

<Results of adsorption rate>
The results of the adsorption rate are shown in Table 8. About the Example sheet | seat bodies 1 and 3 and the comparative example sheet | seat body 2, the relative adsorption rate (%) of each material and three types of anticancer agents, cyclophosphamide, methotrexate, and paclitaxel was described. Furthermore, as a comprehensive evaluation, samples having an adsorption rate of any anticancer agent of 90% or more were evaluated as “A”. Among the anticancer agents used for evaluation, a sample that was less than 90% even in one type was evaluated as “F”.

<Consideration of adsorption rate>
An overall evaluation of “A” was obtained for the example sheet bodies 1 and 3. In particular, the drug molecules of the anticancer drug having a wide range of molecular weights from cyclophosphamide to paclitaxel used in the test can be regarded as adsorbing almost all of the drug molecules of the anticancer drug very well. Further, when the results are seen individually, the example sheet body 1 has a water-swelled resin member in the drug-containing urine absorption layer portion, so that the absorption performance of the drug-containing urine is enhanced. It is presumed that the adsorption rate of the drug molecule of the anticancer agent is probably higher than that of the example sheet 3 due to the improvement of the overall absorption performance. In the comparative example sheet 2 that does not have the adsorbed activated carbon, the adsorption of the low molecular weight drug molecules was greatly reduced. Therefore, adsorbed activated carbon is indispensable to deal with a wide range of drug molecules. Based on the above, anticancer drug-containing urine adsorbent sheet bodies have a wide range of molecular weight anti-cancer agents as shown in the results of performance evaluation of adsorbed activated carbon using a substitute substance and the results of adsorption of anticancer drug by activated carbon itself. It was proved that it can cope with the adsorption of drug molecules of cancer drugs.

  Therefore, the anticancer agent-containing urine adsorbent sheet is suitable for installation around the toilet and is useful for ensuring the safety of patients, medical personnel, and cleaning workers. In particular, the anticancer drug drug molecule adsorbing performance is very good, so it is also effective for measures against secondary contamination through urine. In addition, the constituent materials are relatively inexpensive and can be introduced to the site without a large financial burden. FIG. 4 is a photograph when an anticancer agent-containing urine adsorbent sheet is placed around a toilet (male urinal) in a ward. In particular, it is the usage situation laid on the floor below the toilet. Since the thickness of the anti-cancer agent-containing urine adsorbent sheet itself is 5 mm or less, it is expected that the risk of falls of the patient and the like around the toilet is reduced.

  The anticancer agent-containing urine adsorbing sheet body of the present invention has a higher adsorption performance than the existing water-absorbing sheet and the like, specialized in the adsorption of drug molecules of the anticancer agent. Therefore, hospitals that absorb urine containing highly toxic drugs such as anticancer drugs and improve the safety of patients, healthcare workers, hospital staff, etc. by adsorbing drugs contained in the urine It is an effective material for secondary exposure countermeasures.

DESCRIPTION OF SYMBOLS 1A, 1B Anticancer agent containing urine adsorption sheet body 1S Urine absorption sheet body 10a, 10b Drug-containing urine absorption layer part 11 Activated carbon-containing sheet-like member 12 Fibrous liquid-absorbing sheet member 13 Water-swellable resin member 18 Drug-containing urine absorption First surface of layer portion 19 Second surface of drug-containing urine absorption layer portion 20 Drug-containing urine permeation portion 30 Permeation prevention portion 40 Edge portion 50 Non-slip portion 51 Adhesive portion

Claims (13)

A drug-containing urine absorption layer that absorbs drug-containing urine containing drug molecules of an anti-cancer agent;
A drug-containing urine permeation part that is disposed on the first surface side of the drug-containing urine absorption layer part and transmits the drug-containing urine to the drug-containing urine absorption layer part side;
A urine absorbing sheet body provided with a permeation preventing portion disposed on the second surface side of the drug-containing urine absorption layer portion and preventing leakage of the drug-containing urine from the drug-containing urine absorption layer portion side;
The urine absorbing sheet body is disposed around the toilet bowl,
The drug-containing urine absorption layer portion includes an activated carbon-containing sheet-like member containing adsorbed activated carbon and a fibrous urine absorbing sheet member, and the adsorbed activated carbon has an average pore diameter of 1.7 to 5 nm. Has physical properties,
The drug-containing urine permeation part is a cloth-like member of resin fiber,
The permeation-preventing part is a resin sheet member.   The activated carbon-containing sheet-shaped member is disposed on a first surface side of the drug-containing urine absorption layer portion, and the fibrous urine absorbing sheet member is disposed on a second surface side of the drug-containing urine absorption layer portion. 1. The anticancer agent-containing urine adsorbent sheet body according to 1. A drug-containing urine absorption layer that absorbs drug-containing urine containing drug molecules of an anti-cancer agent;
A drug-containing urine permeation part that is disposed on the first surface side of the drug-containing urine absorption layer part and transmits the drug-containing urine to the drug-containing urine absorption layer part side;
A urine absorbing sheet body provided with a permeation preventing portion disposed on the second surface side of the drug-containing urine absorption layer portion and preventing leakage of the drug-containing urine from the drug-containing urine absorption layer portion side;
The urine absorbing sheet body is disposed around the toilet bowl,
The drug-containing urine absorption layer portion includes an activated carbon-containing sheet-like member containing adsorbed activated carbon, a water-swellable resin member, and a fibrous urine absorbing sheet member, and the adsorbed activated carbon has an average pore diameter. Having physical properties of 1.7-5 nm,
The drug-containing urine permeation part is a cloth-like member of resin fiber,
The permeation-preventing part is a resin sheet member.   The activated carbon-containing sheet-shaped member is disposed on the first surface side of the drug-containing urine absorption layer portion, the fibrous urine absorption sheet member is disposed on the second surface side of the drug-containing urine absorption layer portion, The anti-cancer agent-containing urine adsorbing sheet body according to claim 3, wherein the water-swellable resin member is provided between the activated carbon-containing sheet-like member and the fibrous urine absorbing sheet member.   The anticancer agent-containing urine adsorption sheet according to any one of claims 1 to 4, wherein the drug molecule is a non-volatile molecule.   The anticancer agent-containing urine adsorbent sheet according to any one of claims 1 to 5, wherein the drug molecule has a molecular weight of 100 to 1,000. The adsorbed activated carbon further has a physical property such that the pore volume of pores having a pore diameter of 1 to 100 nm per unit weight of the adsorbed activated carbon is 0.08 cm ³ / g or more as measured by the DH plot method. 7. The anticancer agent-containing urine adsorption sheet according to any one of items 6 to 6.   The anticancer agent-containing urine according to any one of claims 1 to 7, wherein the drug-containing urine permeation part has a water retention rate of 500% or less in a water retention test in accordance with JIS L 1913 (2010). Adsorption sheet body.   The anticancer agent-containing urine adsorbent sheet according to any one of claims 1 to 8, wherein the drug-containing urine permeation part is a nonwoven fabric of synthetic resin fibers. The anticancer agent-containing urine adsorbing sheet body according to any one of claims 1 to 9, wherein the basis weight of the fibrous urine absorbing sheet member is 10 g / m ² or more.   The anticancer agent-containing urine adsorption sheet body according to any one of claims 1 to 10, wherein a non-slip portion is provided on a back surface of the permeation prevention portion.   The thickness when the drug-containing urine permeation part, the drug-containing urine absorption layer part, and the permeation prevention part are laminated in the urine absorption sheet body is 0.3 to 5 mm. The anticancer agent-containing urine adsorption sheet according to any one of the above.   The anticancer agent-containing urine adsorbent sheet body according to any one of claims 1 to 12, wherein the fibrous urine absorbing sheet member is formed of a cellulose component.

Images